Matthew Davids, MD, MMSc
@drmdavids.bsky.social
Hematologist/oncologist, translational CLL investigator, director of lymphoma clinical research @dana-farber, faculty @harvard med. posts are my own & not medical advice
Excited to join the JCO team—will be handling papers focused on lymphoma and CLL! @danafarber.bsky.social
JCO Journals@jco-asco.bsky.social · last mo.JCO welcomes Dr. Matthew Davids, Dana-Farber Cancer Institute, as our newest Associate Editor in hematologic malignancies. Welcome @drmdavids.bsky.social!
Excited to be opening this trial soon @danafarber.bsky.social and several other sites around the globe!
VJHemOnc@vjhemonc.bsky.social · last yr.It was great to catch up with @drmdavids.bsky.social of @danafarber.bsky.social at #iwCLL2025!🎥 Hear as Dr Davids introduces the MAVRiC trial, which will investigate a mutation-guided retreatment strategy using the AV regimen in patients with CLL/SLL in the 2L setting: 👉 buff.ly/aouDK9h #CLLsm
Nir Hacohen from @broadinstitute.org and @massgeneralbrigham.bsky.social kicking off the 3rd annual Intercepting Blood Cancers meeting in Nice! @ireneghobrial.bsky.social
